Further, not all NSCLC erlotinib-resistance mechanisms reported in the literature were exhibited by the PERCs; we found no compelling evidence of transformation to small cell lung cancer, epithelial-to-mesenchymal transition or activation of IGF1R, AXL or NFK-B. Here, NFKB1 is linked to non-small cell lung carcinoma.